KBI Biopharma Acquires Elion Labs
KBI Biopharma, a biopharmaceutical contract development and manufacturing organization, has completed the acquisition of Elion Labs, a Louisville, Colorado-headquartered contract services organization providing services for analytical development and product characterization.
Elion’s services include analytical method development, qualification and validation, characterization of biologics, and data analysis, including visualization and interpretation of complex data sets.
The acquisition adds to KBI’s analytical and biophysical characterization capabilities following the company’s June 2017 acquisition of Alliance Protein Laboratories, a San Diego, California-based analytical services company specializing in biophysical characterization of biopharmaceuticals. KBI also owns a Boulder, Colorado facility that is focused on development and manufacturing of microbial processes and houses some of KBI’s analytical service offerings, such as its Particle Characterization Core Facility. All of Elion’s staff will join KBI, including co-founders John Gabrielson, Brent Kendrick, and Kelly Arthur who will continue to oversee operations at the Louisville facility.
In addition to expanding its existing Durham, North Carolina and Boulder, Colorado facilities, the company has added cell-therapy development and manufacturing at its facility in The Woodlands, Texas, integrated the Selexis cell-line development technology into its mammalian cell-culture development and manufacturing platforms in North Carolina, and completed the acquisition of Alliance Protein Laboratories.
Source: KBI Biopharma